Immunogenicity, Safety, and Clinical Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Spondyloarthritis (Preliminary Data)

Background. Immunosuppressive drugs are widely used for the treatment of patients with spondyloarthritis (SpA) to effectively control the activity of the disease. At the same time, the use of these drugs is associated with an increased risk of developing infections of the upper and lower respiratory tract, which can be prevented by vaccination. The aim of the study was to evaluate the immunogenicity, safety, and clinical efficacy of the 23-valent pneumococcal  polysaccharide vaccine (PPV-23) in patients with SpA. Material and methods. The study included 54 patients with SpA: 39 with ankylosing spondylitis, and 15 with psoriatic arthritis. Most patients had a history of two or more cases of lower respiratory tract infections, 2 patients reported a monthly exacerbation of chronic sinusitis, one patient reported the development of otitis every 2–3 months. 72% of patients received immunosuppressive therapy at the time of inclusion in the study. PPV-23 was administered in the amount of 1 dose (0.5 ml) against the background of ongoing antirheumatic therapy. The level of antibodies to pneumococcal capsular polysaccharide was determined using the EIA PCP IgG kit (TestLine Clinical Diagnostics s.r.o., Czech Republic) at baseline, after 1, 3, and 12 months after vaccination. The tolerability of PPV-23, the effect of vaccination on SpA activity (according to the dynamics of the BASDAI index), and the incidence of upper and lower respiratory tract infections were assessed. Results. The concentration of antibodies to pneumococcal capsular polysaccharide was significantly higher 1, 3, and 12 months after vaccination compared to baseline. There was no negative effect of vaccination on the activity of SpA and the emergence of «new» autoimmune disorders. The vaccine was well tolerated by 76% of patients., Only one patient developed pneumonia during the observation period. Patients suffering from frequent sinusitis and otitis reported the absence of these infections after vaccination. Conclusions. Preliminary results of the study indicate sufficient immunogenicity, safety, and clinical efficacy of PPV-23 in patients with SpA.

1. Available at: https://www.who.int/immunization/monitoring_surveillance/burden/vpd/17_WHO_SurveillanceVaccinePreventable_17_Pneumo_Russian_R1.pdf. Accessed: 25th January 2022

2. Broyde A., Arad U., Madar-Balakirski N. et al. Long-term Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases. J Rheumatol. 2016; 43 (2): 267–72. doi: 10.3899/jrheum.150397.

3. Baranova M.M., Muravyeva N.V., Belov B.S. The frequency and structure of comorbid infections in patients with spondyloarthritis (preliminary own data). Meditsinskiy sovet = Medical Council. 2021; 2: 122–126 (in Russian)

4. Muravyeva N.V., Belov B.S., Baranova M.M., Korotaeva T.V. Comorbid infections in spondyloarthritis: a modern view of the problem. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020; 14 (4): 103–110. doi: 10.14412/1996-7012-2020-4-103-110 (in Russian)

5. Atzeni F., Sarzi-Puttini P., Sebastiani M. et al. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the italian registry GISEA. Clin Exp Rheumatol. 2019; 37 (4): 649–655.

6. Chung H.Y., Tam L.S., Chan S.C.W. et al. Risk of Community-Acquired Pneumonia Requiring Hospitalization in Patients with Spondyloarthritis. Ther Adv Musculoskelet Dis. 2020; 12: 1759720X20962618. doi: 10.1177/1759720X20962618.

7. Furer V., Rondaan C., Heijstek M. et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): A systemic literature review informing the 2019 Update of the EULAR Recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; 5 (2): e001041. doi: 10.1136/rmdopen-2019-001041.

8. Furer V., Rondaan C., Heijstek M.W. et al. 2019 Update of EULAR recommendations for vaccination in adultpatients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79 (1): 39–52. doi: 10.1136/annrheumdis-2019-215882.

9. Baranova M.M., Muravyeva N.V., Belov B.S. et al. Comorbid infections in patients with spondyloarthritis: frequency, structure, prevention. The eighteenth scientific and practical conference «Problems of modern rheumatology». November 27, 2021, Moscow. Collection of scientific works. Moscow:, ANO «Commonwealth of Rheumatologists». 2021; 23–26. (in Russian)

10. Brocq O., Acquacalda E., Berthier F. et al. Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study. Joint Bone Spine. 2016; 83 (2): 155–159. doi: 10.1016/j.jbspin.2015.11.005.

11. Lejri-El Euchi H., Chirpaz E. et al. Vaccination against influenza and pneumococcal infections in patients with autoimmune disorders under biological therapy: Coverage and attitudes in patients and physicians. Eur J Intern Med. 2019; 69: 25–31. doi: 10.1016/j.ejim.2019.08.010.

12. WHO. Training manual for Streptococcus Pneumoniae serotype specific IgG (PN PS ELISA). Available at: http://www.vaccine.uab.edu/ELISA%20protocol.pdf. Accessed: 20th January 2022.

13. Van Aalst M., Langedijk A.C., Spijker R. et al. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine. 2018; 36 (39): 5832–5845. doi: 10.1016/j.vaccine.2018.07.039.

14. Rákóczi É., Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 2017; 3: e000484. doi:10.1136/rmdopen-2017-000484.

15. Rasmussen S.L., Fuursted K., Nielsen K.A. et al. Pneumococcal antibody protection in patients with autoimmune inflammatory rheumatic diseases with varying vaccination status. Scand J Rheumatol. 2020; 49 (5): 353–360. doi: 10.1080/03009742.2020.1732459.

16. Bühler S., Eperon G., Ribi C. et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015; 145: w14159. doi: 10.4414/smw.2015.14159.